Patient or population: children and adults infected with mpox Setting: UK, USA, Central African Republic Intervention: tecovirimata
Outcomes	Number of events with tecovirimat n (%)	No. of participants (studies)	Comment
Serious adverse events	2 (0.6%)	355 (3)	Two out of 355 participants treated with tecovirimat across three studies reported serious adverse events, including one case of elevated liver enzyme levels and one case of severe anaemia.
Other adverse events	11 (3.2%)	340 (1)	Eleven out of 340 participants treated with tecovirimat across one study reported other adverse events.
Mortality	1 (7%)	14 (1)	One participant out of 14 treated with tecovirimat across one study died.
Mental health outcomes	2 (0.6%)	341 (2)	Two participants out of 341 treated with tecovirimat across two studies reported mental health outcomes, including low mood and hospitalization for psychiatric reasons.
Footnotes aThe included studies do not include control populations; therefore, there are no comparison statistics included in the results table and no GRADE assessment has been performed. We judged these studies to be at critical risk of bias due to an observational, non‐comparative study design.